Completed PHASE2 INTERVENTIONAL NCT00006399

Effects of Estrogen on Memory in Post-Menopausal Women and Patients With Alzheimer's Disease

Estrogen Modulation Effects on Cholinergic Function in Normal Post-Menopausal Women and Patients With Alzheimer's Disease

Sponsor: Alzheimer's Association

Conditions Alzheimer Disease

Interventions Donepezil Estrogen Progesterone

Updated 5 times since 2017 Last updated: Jan 13, 2009 Started: Sep 30, 1999 Primary completion: Mar 31, 2004 Completion: Mar 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Alzheimer Disease and is currently completed. Alzheimer's Association leads this study, which shows 5 recorded versions since 1999 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Alzheimer's Association
Eisai Inc.
National Center for Research Resources (NCRR)
Pfizer

Data source: National Institute on Aging (NIA)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Burlington, United States